Opportunities in smallcaps header image 2

The Foamix And Menlo Merger Makes Sense

December 10th, 2019 · No Comments

  • The all-stock merger between Foamix and Menlo has been badly received by the markets, but we beg to differ.
  • Basically, the merger reduces cost, risk and leverages the critical sales infrastructure already 90% in place for the upcoming launch of AMZEEQ in January.
  • There is a deal of uncertainty, as the post-merger ownership ratio depends a lot on the outcomes of two Phase III trials of Menlo’s Serlopitant.
  • We think that uncertainty has been sensibly dealt with, as failure in one or both of these tests significantly reduces Menlo’s post-merger ownership stake.

Source: The Foamix And Menlo Merger Makes Sense – Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) | Seeking Alpha

Tags: FOMX